2013

WCCT Global launches international patient recruitment services, implements bedside data capture

Monday, December 2, 2013

Southern California-based CRO WCCT Global has implemented an international patient recruitment strategy, led by the use of an in-depth social media strategy and optimized search engine approach. WCCT Global has a complete design team able to produce any print materials needed for a campaign in any language. Each print material for a study is connected to a digital website where the viewer can scan with his or her smart phone and sign up for a study without having to make a phone call.

[Read More]

SillaJen to acquire Jennerex

Wednesday, November 27, 2013

SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.

[Read More]

Cincinnati area hospitals, universities form collaborative IRB

Wednesday, November 27, 2013

A group of hospitals and research institutions across Cincinnati and Northern Kentucky has formed a collaborative Institutional Review Board (IRB) agreement that will allow any of the six participating sites to serve as the IRB of record for research conducted across multiple participating study sites.

[Read More]

Genomic Health, Almac collaborate on test to predict chemotherapy benefits

Wednesday, November 27, 2013

Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer.  Such a test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score. 

[Read More]